SBRT and two targeted drugs for advanced nasopharyngeal cancer
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests a combination of focused radiation (SBRT) and two targeted drugs (nimotuzumab and tislelizumab) for people with nasopharyngeal cancer that has come back or spread to a few spots (1-5) after prior immunotherapy. It aims to see if this triple therapy can help control the disease when standard treatment has stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of non-keratinizing nasopharyngeal cancer (a specific type of throat cancer).
- Your cancer has returned or spread to 1-5 new spots after you've already tried an anti-PD-1 immunotherapy (like pembrolizumab or nivolumab).
- You are between 18 and 75 years old.
- Your liver, kidney, and blood cell counts must be within certain healthy ranges (your doctor will check).
- You must not have had any other types of cancer in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
This trial tests a shorter course of the immunotherapy drug tislelizumab combined with standard chemotherapy and radiation for a specific type of nasopharyngeal cancer. It aims to see if this approach is safe and effective for patients with advanced-stage disease.
This trial tests combining low-dose radiation with an immunotherapy drug (toripalimab) and chemotherapy for people whose nose and throat cancer has come back or spread. The goal is to see if this combination works better than standard treatments.
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) after standard induction chemotherapy helps keep advanced nasopharyngeal cancer from coming back. It is for people who have completed 3 cycles of GP chemotherapy combined with a PD-1 inhibitor and have not had their cancer progress.
This trial tests whether a targeted radiation therapy, combined with the immunotherapy drug toripalimab before and after treatment, can reduce side effects while still effectively treating nasopharyngeal cancer. It is for patients with certain tumor sizes or stages who have not had prior neck radiation or immunotherapy.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.